What Is Tissue Metabolomics Metabolomics measures the complete set of small molecule metabolites in a biological sample. Applying it to HCC tissue allows researchers to directly characterize how tumor cells rewire their energy and biosynthetic metabolism.
The Study This study used gas chromatography-mass spectrometry (GC-MS) to measure metabolite profiles in paired HCC tumor and adjacent non-tumor liver tissue from a cohort of patients with diverse etiologies.
Key Question The researchers asked whether metabolic reprogramming in HCC is uniform across tumors or differs by molecular subtype, and what these patterns reveal about tumor biology and potential treatment targets.
Sample Collection Paired HCC tumor and adjacent non-tumor liver tissue were collected from patients at the time of surgical resection. This design allowed within-patient comparison to control for individual metabolic baselines.
GC-MS Analysis Metabolites were extracted, derivatized, and analyzed by gas chromatography-mass spectrometry. This platform quantifies hundreds of primary metabolites including amino acids, organic acids, sugars, and lipid intermediates.
Transcriptomic Integration Metabolic data were linked to previously established transcriptomic subclassifications of HCC, allowing exploration of whether metabolic phenotypes align with gene expression subtypes.
Warburg Effect in HCC Glucose and glycolytic intermediates were markedly elevated in HCC tumors compared to adjacent liver tissue. The overall increase in glycolytic flux was approximately fourfold, consistent with the Warburg effect described in many cancer types.
Lactate Accumulation Elevated lactate in tumor tissue further confirmed aerobic glycolysis as a dominant energy pathway. This metabolic shift allows rapid ATP production and supplies biosynthetic precursors needed for tumor growth.
Therapeutic Relevance The uniform glycolytic upregulation across HCC subtypes suggests that inhibiting glycolysis - for example with 2-deoxy-glucose or hexokinase inhibitors - could have broad anti-tumor activity regardless of molecular subtype.
Transcriptomic G1 Subtype HCC tumors classified as G1 (associated with HBV infection and chromosomal instability) showed a distinct metabolic profile compared to other subtypes, particularly in lipid handling.
Lipid Catabolism Activation G1 tumors displayed elevated levels of fatty acid oxidation intermediates, suggesting enhanced beta-oxidation as an energy source. This contrasts with the glycolysis-dominant metabolism seen in other subtypes.
Biological Implications The coexistence of glycolytic and lipid catabolic programs in different HCC subtypes indicates metabolic plasticity and heterogeneity. Therapeutic strategies may need to be subtype-directed to effectively target tumor metabolism.
Amino Acid Patterns Several amino acids including glutamine and branched-chain amino acids were depleted in HCC tumor tissue relative to adjacent liver. This reflects increased consumption for biosynthesis and energy, consistent with high anabolic demand in rapidly proliferating cells.
TCA Cycle Intermediates Alterations in TCA cycle metabolites were observed, with tumor-specific patterns suggesting incomplete TCA activity or shunting of intermediates toward biosynthetic pathways such as lipid synthesis and nucleotide production.
Glutamine Dependency The depletion of glutamine in tumor tissue, combined with elevated downstream metabolites, suggests HCC tumors are highly glutamine-dependent, pointing to glutaminase inhibition as a potential therapeutic approach.
Metabolic Biomarkers Tumor metabolite profiles may inform prognosis or treatment selection. Specific metabolic signatures could serve as biomarkers measurable in blood or urine, potentially enabling less invasive disease monitoring.
Targeting HCC Metabolism The convergence of glycolytic upregulation across subtypes, combined with subtype-specific lipid or amino acid alterations, suggests a tiered metabolic targeting strategy: broad glycolysis inhibition combined with subtype-specific secondary targets.
Drug Repurposing Existing metabolic drugs used in other conditions - such as metformin (complex I inhibitor) or statins (cholesterol synthesis inhibitors) - may have activity against specific HCC metabolic vulnerabilities and warrant clinical investigation.